Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study

doi:10.1186/s12877-019-1401-y

CNU IR > College of Smart Living > Dept. of Hospital and Health (including master's program) > Periodical Articles > Item 310902800/32507

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32507

Title:	Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study
Authors:	Wang, Yi-Chi Chen, Yung-Liang Huang, Chun-Che Chung-Han Ho(何宗翰) Huang, Yu-Tung Wu, Ming-Ping Ou, Ming-Jung Yang, Chiu-Hsien Chen, Ping-Jen
Contributors:	Kaohsiung Med Univ, Kaohsiung Municipal Hsiao Kang Hosp, Dept Family Med Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Family Med I Shou Univ, Coll Med, Dept Healthcare Adm Chi Mei Med Ctr, Dept Med Res Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm Chang Gung Mem Hosp, Ctr Big Data Analyt & Stat Chi Mei Fdn Hosp, Dept Obstet & Gynecol, Div Urogynecol Fu Jan Catholic Univ, Coll Med, Dept Obstet & Gynecol Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Family Med Kaohsiung Med Univ, Coll Med, Sch Med UCL, Marie Curie Palliat Care Res Dept, Div Psychiat Chi Mei Med Ctr, Palliat Care Ctr
Keywords:	Anticholinergics Cohort study Cumulative defined daily doses Dementia Lower urinary tract symptoms
Date:	2019
Issue Date:	2020-07-29 13:47:49 (UTC+8)
Publisher:	BMC
Abstract:	Background: Studies have shown an association between lower urinary tract symptoms (LUTS) and an increased risk of dementia. Whether anticholinergic use contributes to the development of dementia in patients with LUTS remains unknown, especially in Asian populations. This study aims to investigate the association between anticholinergic use and dementia in patients with LUTS. Methods: This study included patients aged 50 years and over with newly diagnosed LUTS (January 2001 to December 2005), divided into four groups according to their cumulative defined daily doses (cDDDs) of anticholinergics: < 28 cDDDs, 28-84 cDDDs, 85-336 cDDDs, >= 337 cDDDs. Patients were followed up until dementia developed or until the end of 2012. Results: We recruited a total of 16,412 patients. The incidence of dementia was 10% in the < 28 cDDD group, 8.9% in the 28-84 cDDD group, 11.5% in the 85-336 cDDD group, and 14.4% in the >= 337 cDDD group (p =.005). In a Cox proportional hazards analysis, the adjusted hazard ratio of dementia was 1.15 (95% CI = 0.97-1.37) in the 85336 cDDD group, and 1.40 (95% CI = 1.12-1.75) in the >= 337 cDDD group after adjusting for covariates. Conclusions: Our study indicates that higher cumulative anticholinergic exposure is associated with an increase in the risk of incident dementia in patients with LUTS aged 50 years of age and over. Either using one anticholinergic agent or switching anticholinergic agents cumulatively increases this risk. Therapeutic risks and benefits of using anticholinergics in LUTS treatment should be clinically reviewed and weighed.
Relation:	Bmc Geriatrics, v.19, n.1, pp.380
Appears in Collections:	[Dept. of Hospital and Health (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
10.1186-s12877-019-1401-y.pdf		765Kb	Adobe PDF	374	View/Open
index.html		0Kb	HTML	1331	View/Open

Loading...